We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Shire has submitted a new drug application (NDA) to the FDA for its investigational compound guanfacine extended release, which, if approved, would be the first once-daily selective alpha-2A-adrenoceptor agonist for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children ages 6 to 17.
Starpharma has begun a Phase I safety trial in men for its lead product VivaGel (SPL7013). VivaGel is a microbicide for the prevention of the sexually transmitted infections, including genital herpes and HIV.
CuraGen and TopoTarget announced that Southwest Oncology Group, a national clinical trials cooperative group, has begun a Phase II trial to test the effects of an investigational agent on aggressive
B-cell lymphoma.
Neurobiological Technologies has completed its the site selection for its first global Phase III trial for Viprinex (ancrod injection) in acute ischemic stroke.
Oncolytics Biotech Inc. has completed patient enrolment in its Phase I U.S. clinical trial investigating the systemic delivery of Reolysin to treat patients with advanced cancers.